We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ELIX Elixirr International Plc

5.00 (1.09%)
05 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Elixirr International Plc LSE:ELIX London Ordinary Share GB00BLPHTX84 ORD 0.005P
  Price Change % Change Share Price Shares Traded Last Trade
  5.00 1.09% 465.00 2,604 08:00:00
Bid Price Offer Price High Price Low Price Open Price
460.00 470.00 465.00 465.00 465.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Management Consulting Svcs 70.7M 12.87M 0.2786 16.69 214.77M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:22:18 O 2 470.00 GBX

Elixirr (ELIX) Latest News

Elixirr (ELIX) Discussions and Chat

Elixirr Forums and Chat

Date Time Title Posts
06/11/202311:41ELIXIRR The Challenger Consultancy122
11/10/202312:13ELIXIRR - The Challenger Consultancy - 2023 9
09/7/202018:13ELIXRR The Challenger consultancy-

Add a New Thread

Elixirr (ELIX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Elixirr (ELIX) Top Chat Posts

Top Posts
Posted at 05/12/2023 08:20 by Elixirr Daily Update
Elixirr International Plc is listed in the Management Consulting Svcs sector of the London Stock Exchange with ticker ELIX. The last closing price for Elixirr was 460p.
Elixirr currently has 46,186,481 shares in issue. The market capitalisation of Elixirr is £214,767,137.
Elixirr has a price to earnings ratio (PE ratio) of 16.69.
This morning ELIX shares opened at 465p
Posted at 06/11/2023 11:41 by simon gordon
On the iOLAP website they have twenty vacancies, business must be strong.

Thought this a decent summary:

Investors Chronicle - 7/9/23

A capital-light consultancy with excellent momentum

Boutique consultancies do not often crop up on the public market. Pay attention when they do.

by Jemma Slingo

“The concept of a structured work-life balance almost seems to be expected in today’s society – especially in a typical 9-to-5 role, but I think it should be seen as a privilege.” So says Stephen Newton, founder and chief executive of Elixirr (ELIX), a management consultancy that joined Aim three years ago. It’s a fitting message from an entrepreneur set on driving growth and trimming the fat.

Elixirr presents itself as a new breed of management consultancy. It used a recent ad campaign to lampoon the industry’s jargon, swagger and reliance on under-experienced Oxbridge graduates, and continually stresses its “challenger” credentials. While it suffers from some of its peers’ breathless fervour, describing its workforce as “creative storytellers”, “brave contrarians” and “probing observers”, its genuine promise makes this just about palatable.

Punching above its weight

With a market cap of under £250mn, Elixirr is small – even compared with specialist listed consulting peers such as Alpha Financial Markets Consulting (AFM) and XPS Pensions (XPS). However, it benefits from a similarly capital-light business model and excellent momentum. Indeed, according to Investec, Elixirr is the fastest-growing management consultancy in the UK and the third-fastest in Europe. Having increased its market share every year since 2011 and posted organic revenue growth of 18 per cent in 2022, Elixirr has momentum. With an adjusted Ebitda (earnings before interest, tax, depreciation and amortisation) margin at around 30 per cent, it is also profitable.

The company was founded in the aftermath of the financial crash, and originally focused on financial services work, which is Newton’s area of expertise. Around half of group turnover still comes from the sector, but Elixirr is rapidly diversifying, and its 200-strong client base now includes names as varied and big-ticket as Diageo, LVMH, Tesla and Burger King.

The fact that big names are on board suggests this youthful small cap is an increasingly viable alternative to the ‘Big Four’ professional services firms and strategy houses such as McKinsey, Boston Consulting Group and Bain, which together account for almost half of the market.

A lot of the people who work at Elixirr cut their teeth in this world, so they know what they’re up against. Newton was formerly a managing partner at Accenture, while chief financial officer Graham Busby worked in Accenture’s ‘global mega-deal’ department. The quality of the wider management team is also encouraging, with former BT chief executive Gavin Patterson acting as non-executive chair.

The big question is whether Elixirr can keep luring talented people away from the corporate behemoths. The group has about 500 consultants but just 21 of them are client-facing partners. As partners generate the biggest invoices and bring in most of the work, swelling their ranks will be crucial for growth.

In this sense, Elixirr has a lot in common with Keystone Law (KEYS), whose success relies on a team of 400 senior solicitors and which has seen recruitment slow down in recent months. However, while Keystone’s self-employed “principals” take a chunk of what they bill and are enticed by the promise of flexible working, Elixirr depends heavily on share-based compensation.

Management claims that partners can earn 80 per cent more at Elixirr than they could at a big rival firm because, while cash remuneration is lower, the money saved on pay packets is pumped back into the business, fuelling equity returns.

“By investing £3.2mn in the business over five years and assuming 25 per cent compound annual growth rate (CAGR) share price growth, each partner can achieve an equity return of £7.2mn,” declares Elixirr, which loans new partners £500,000 to buy shares. It concludes that over a five-year period a partner can earn £9mn (including cash remuneration) compared with £5mn at a Big Four firm.

Non-partners are also strongly equity incentivised via share options and an employee share purchase plan.

On the one hand, this approach makes a lot of sense. One of the big conundrums posed by listed people businesses is how to align the interests of partners with those of external investors. Why would partners want to return profit to shareholders if they could distribute it all among themselves? Elixirr’s focus on equity means everyone is singing from the same hymn sheet. However, its logic falls apart if shares head south and partners watch their pay prospects wither.

Share dilution is therefore something to watch for. Management stressed that the “value created from our equity incentive schemes far outweighs the potential dilutive effect” and analysts note that there has been no material dilution to the share count since April 2021. As the business keeps scaling up, however, it remains a risk.

Growing pains

Organic growth is not Elixirr’s only option, of course. It recently deployed some cash to acquire iOLAP, a US consultancy specialising in data and analytics. The deal makes strategic sense and is reminiscent of Alpha FMC’s Lionpoint purchase. Elixirr now has a sizable presence in the US, home to the world’s biggest consultancy market, and should benefit from plenty of cross-selling opportunities.

It’s not easy to scale up a business at pace however, and Alpha FMC’s recent performance spotlights some of the problems that Elixirr could face. Fears about under-utilised consultants marred Alpha FMC’s latest annual results, where the group cited industry-wide “increased levels of competition as a result of overcapacity”. Its shares have fallen by 25 per cent since the start of the year after a bumper three-year period.

Elixirr has a more varied client base than Alpha FMC, but it is not immune to market conditions. Staff costs as a percentage of revenues have risen over the past four years, and margins could suffer if work dries up. To make things worse, it is tricky to predict when or if a downturn is coming as contracts only last for four to eight weeks on average, limiting visibility and management’s capacity to plan.

The firm’s resilience has been tested before, though: in 2020, the group achieved revenue growth of 24 per cent while the consulting market as a whole shrank by 18 per cent. Elixirr’s balance sheet is also reassuringly robust. The group has a net cash position, despite several acquisitions and dividend payments, and operations have proved reliably cash-generative so far: standard payment terms require settlement of invoices within 30 days of receipt, and the majority of trade receivables are less than 31 days old.

Valuing potential

Elixirr's share price has risen by 165 per cent since its IPO, so potential investors can be forgiven for feeling as though they’ve missed the boat. Small-cap valuations are slippery at the best of times, and the lack of publicly traded consultancies – together with a dearth of analyst coverage – makes valuing Elixirr even harder. However, there does appear to be a disconnect between its growth prospects and its price/earnings (PE) multiple.

Analysis by Investec puts Elixirr on a PE ratio of 15.4 for the 2023 calendar year, despite a forecast sales CAGR for 2022-24 of 17 per cent. By contrast, Alpha FMC is expected to grow by 10 per cent but trades on a PE ratio of 18.1.

Some will argue that Elixirr is cheap because it is small and risky. It has a short track record on the public market and is not widely covered by analysts. It is also exposed to partner and client exits, and its top three clients account for about a fifth of sales.

On balance, however, the risk-reward balance looks enticing. As a capital-light sector challenger, Elixirr’s momentum could well persist for years to come. Taken together, profitable growth, a burgeoning client base and US expansion plans make for an intoxicating mixture.
Posted at 23/10/2023 07:18 by harry davis
Very harsh share price reaction isnt it rimau, the company is very good. The valuation makes more sense now
Posted at 06/10/2023 08:14 by someuwin
Nothing stock specific about yesterday's drop imo. Just the general small cap weakness. Plus, this is a very thinly traded stock which magnifies the falls (and rises).

Now almost 100% gain to get to Cavendish's recently published 998p target price. Longer term I fully expect ELIX to list in US.
Posted at 05/10/2023 18:01 by eagle eye
No significant volume today but a delayed trade of 10,877 shares went through at 473.5p.
Market makers were looking for buyers and were happy to mark the price down.
Maybe a probate case where the bank just instructs the broker to sell and they don't care what price they get.
Posted at 27/9/2023 11:26 by someuwin
Part of Cavendish's ELIX note last week...

"Digital + data + AI = significant growth potential

Elixirr’s ambition is to become the best digital, data, AI and strategy consultancy in the world and H1 results evidence strong progress towards this aim. H1 sales grew +23% (+14% organic), adj. EBITDA +19%, margins strong at 30%, adj. EPS +23% and net cash £20m. Revenue per partner grew by +24%, supported by a broadening range of capabilities that have been further strengthened by the acquisition of Responsum, a US-headquartered AI specialist. Elixirr also continues to attract highly experienced Partners and consultants and promote talent from within, all of which support the long-term growth prospects in a $266bn global market. Guidance for FY23E is unchanged and, at this stage, we have assumed no change to FY 2024E and FY 2025E EPS from the acquisition of Responsum. However, as Elixirr has already worked closely alongside the business on several client engagements and identified 40+ client opportunities, it is a likely source of future, potentially material, upgrades. Elixirr is valued at half peer Accenture’s valuation for twice the forecast growth, and we maintain our 998p price target (+74% upside)."

Note: Accenture (NYSE:ACN) Current valuation $206.34Bn = £165.56Bn so 620 times bigger than ELIX.
Posted at 26/9/2023 10:16 by someuwin
I missed a few of the logos from the ELIX client list I posted above. A few more big names here...

See case studies here...
Posted at 18/9/2023 12:49 by kalai1
Bango posted its Interims for the 6 months ended 30th June 2023 this morning. Revenue was up 88% to $20.3M, in line with management expectations. ARR grew to $5.6M and this growth will accelerate as DVM contracts won in 1H23 launch. Meanwhile profit margins remain healthy with the gross profit margin remaining high at 90% in 1H23. And margins could improve even more in H2, actions to deliver $19M of the $21M of guided cost synergies are already complete and the benefit will materialize through 2H23. Guidance given was encouraging as well, the business is on track to meet consensus market expectations for the full year and increasing adjusted EBITDA margins should deliver a substantial increase in adjusted EBITDA for FY24. Valuation look reasonably attractive with forward PE ratio at 13.7x in the top third for the Software & IT Services sector, PEG ratio at 0.2x is top decile. Share price has been drifting sideways for nearly 3 years now and lacks positive momentum, but this is likely to change over the next 3 years as the group moves more lastingly into statutory profit. Certainly worth monitoring for the medium and longer run...

...from WealthOracle
Posted at 18/9/2023 11:39 by kalai1
Elixirr plc posted Interims for H1 2023 this morning. Revenue was up 23% to £41.1m and the Group delivered record revenue in three of the six months in the period. There was a 9% increase in adjusted EBITDA compared to H1 22 totalling £12.3m, maintaining the Group’s strong track record of profitability with an adjusted EBITDA margin of 30%. Adjusted diluted EPS was up 23% to 18.5p. The balance sheet remains strong, net cash was £19.5m with no debt. Valuation remains ok with forward PE ratio 3rd quartile for the sector at 15.7x following a robust break higher since late August. But the share has traded on much higher multiples in recent years and valuation should not be a constraint on further gains. Meanwhile the share is building some short-term momentum. BUY...

...from WealthOracle
Posted at 18/9/2023 11:39 by eagle eye
Well done to everyone at ELIX.
It looks like business as usual.
No change to forecasts but looks an interesting acquisition.
Well under the radar as this is the first post of the day!
Posted at 30/8/2023 15:56 by rimau1
Interim results this month. Elix has held up comparatively well. High quality niche operator but will it still be outperforming with the current macro headwinds. Not long to wait.
Elixirr share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |